Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition
NCT03174236Phase 3Unknown
- Sponsor
- University of Oxford
- Start
- Sep 2017
- Primary completion
- Jan 2020
- Modality
- Reversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ceftriaxone and metronidazole in severe acute malnutrition (SAM) (4 arms), sponsored by University of Oxford. Primary endpoint: Mortality at 90 days. Status: unknown.
02
Drugs
ceftriaxonemetronidazole
03
Conditions
severe acute malnutrition (SAM)
Beyond the preview
Go deeper on NCT03174236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174236.